BioPharma Reporter

AUGUST 2, 2022

GreenLight Biosciences and Samsung Biologics have completed the first commercial-scale engineering run under the companiesâ mRNA production partnership: ahead of a COVID-19 vaccine booster clinical trial due to start later this year.

Engineer 52

Engineer Vaccination Vaccine Clinical Trials 52

STAT News

NOVEMBER 15, 2022

As the Covid-19 pandemic spread across the world two years ago, one of India’s leading biotech companies was racing to develop a vaccine with crucial backing from the Indian government. Read the rest…

Vaccination 145

Vaccination Vaccine Engineer Clinical Trials 145

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 22, 2022

The Indian Institute of Science (IISc), Centre for BioSystems Science and Engineering, has designed a new method to deliver a vaccine candidate for tuberculosis (TB). The research involves using spherical vesicles secreted by bacteria coated on gold nanoparticles which can then be delivered to the immune cells.

Vaccination 100

Vaccination Vaccine Research Bacteria 100

BioTech 365

SEPTEMBER 7, 2021

CSE: DTC FSE: DTC OTC: DTCFF PRESS RELEASE DEFENCE THERAPEUTICS DEVELOPMENT PROGRAM TO ENGINEER A NEW HPV VACCINE … Continue reading → . / Key word(s): Miscellaneous 07.09.2021 / 08:30 The issuer is solely responsible for the content of this announcement.

Engineer 40

Engineer Vaccination Vaccine Development 40

Advarra

MARCH 31, 2023

The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. A key part of the IBC’s evaluation is assessing the risks posed by the engineered genetic materials.

Engineer 52

Engineer Genetics Clinical Research Research 52

BioPharma Reporter

SEPTEMBER 14, 2023

Vaxess Technologies, a life sciences company developing a shelf-stable vaccine patch with potential for self-application, has announced an additional $9 million in venture capital funding, with investors including RA Capital, The Engine, and GHIC, and Ulu Ventures.

Vaccination 64

Vaccination Vaccine Life Science Engineer 64

Drug Discovery World

MARCH 21, 2023

In a step forward for genetic engineering and synthetic biology, US researchers have modified E coli bacteria to be immune to infection by all natural viruses tested so far. Genetic engineering The findings build on earlier efforts by genetic engineers, which involved genetically reprogramming E.

Engineer 52

Engineer Genetic Engineering Scientist Bacteria 52

Drug Discovery World

FEBRUARY 14, 2024

Vaccination responses need to be rapid, efficacious and cost-effective if they are to outpace new viral threats emerging across the globe, says Jian He (Jason) , Chemistry, Manufacturing and Controls (CMC) Head, WuXi Vaccines. This would give more people much faster access to more effective vaccines.

Protein 59

Protein Vaccination Vaccine Manufacturing 59

Drug Discovery World

FEBRUARY 20, 2024

A five-year contract totalling up to $31 million including programme options has been awarded to Ginkgo Bioworks to discover and develop next-generation vaccine adjuvants. The post Ginkgo Bioworks to discover and develop novel vaccine adjuvants appeared first on Drug Discovery World (DDW).

Vaccination 52

Vaccination Vaccine Development Immune Response 52

Scienmag

MARCH 22, 2021

Credit: UNM School of Engineering A University of New Mexico research team conducted a data analysis that has found that as a larger portion of the population gets vaccinated against COVID-19, it becomes economically advantageous to start relaxing social distancing measures and open businesses.

Vaccination 94

Vaccination Vaccine Engineer Research 94

Scienmag

MARCH 10, 2022

Close interactions with infectious disease set both University of California, Santa Cruz graduate student Ana Nuñez Castrejon and Associate Professor of Biomolecular Engineering Rebecca DuBois on the path of studying Respiratory syncytial virus (RSV), a common and sometimes dangerous respiratory disease for which there is not currently a vaccine.

Immune Response 77

Immune Response Vaccination Vaccine Protein 77

Scienmag

OCTOBER 12, 2020

Credit: WEI Wei Exploration of new leukemia antigens and construction of appropriate delivery systems using FDA-approved material are important strategies for developing leukemia vaccines for clinic use.

Vaccination 93

Vaccination Vaccine Development Scientist 93

XTalks

SEPTEMBER 21, 2023

announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. Since 2004, the NIAID has been championing the discovery and development of the cytomegalovirus (CMV) vector used to deliver the HIV vaccine material to the immune system without causing disease.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Advarra

JANUARY 11, 2024

While mRNA usage has played several roles in clinical research , oncology researchers in particular are eager to explore the possibilities of mRNA-based cancer vaccines. The mRNA constructs used in COVID-19 vaccines, for example, direct cells to produce a version of the “spike” protein studding the surface of SARS-CoV-2.

Vaccination 52

Vaccination Vaccine Protein Antibody 52

The Pharma Data

MAY 14, 2021

Product Name: Face Engineering Exercises For Lifting Face Muscles And Skin. Click here to get Face Engineering Exercises For Lifting Face Muscles And Skin at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors.

Engineer 52

Engineer Production Vaccination Vaccine 52

Drug Discovery World

NOVEMBER 30, 2022

The University of Queensland is set to take a second-generation molecular clamp vaccine to a proof-of-concept human trial. . million to support further development of the re-engineered technology for use in the global response to future disease outbreaks. . Clamp technology . The University of Queensland. .

Vaccination 52

Vaccination Vaccine Immune Response Engineer 52

BioSpace

AUGUST 6, 2020

CoV2373, a recombinant vaccine engineered from the genetic sequence of SARS-CoV-2, in India and in low- and middle-income countries. Novavax said the agreement will allow for the development and distribution of NVX?CoV2373,

Vaccination 98

Vaccination Vaccine Development Engineer 98

pharmaphorum

AUGUST 23, 2021

The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.

DNA 98

DNA Vaccination Vaccine Genetic Engineering 98

BioTech 365

SEPTEMBER 20, 2021

CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE DEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 … Continue reading → . / Key word(s): Miscellaneous 20.09.2021 / 08:30 The issuer is solely responsible for the content of this announcement.

Engineer 40

Engineer Vaccination Vaccine 40

pharmaphorum

SEPTEMBER 10, 2020

The programme is still in the early stages of development, but if it works in trials would provide another approach to prevent transmission of SARS-CoV-2, the virus that causes COVID-19, alongside vaccines and prophylactic antibodies. subtilis spores engineered to present SARS-CoV-2 antigens to the mucosal immune system.

Vaccination 133

Vaccination Vaccine Bacterium Antibody 133

pharmaphorum

MARCH 2, 2021

The COVID-19 pandemic brought life-changing disruptions to people around the world and has turned the typical vaccine R&D process on its head. A combination of urgent need, unprecedented investments, and advances in genetic engineering has allowed what was once mere speculation to become not only our reality, but our future.

Genetics 52

Genetics Vaccination Vaccine Development 52

XTalks

NOVEMBER 23, 2020

Adding to recent announcements from Pfizer and Moderna on the efficacy of their COVID-19 vaccine candidates, AstraZeneca and Oxford revealed today that their vaccine contender is 70 percent effective, and could be as high as 90 percent. Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials.

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

Scienmag

MARCH 11, 2022

11, 2022— Physicists, chemists and immunologists at McMaster University have teamed up to modify red blood cells to transport viral agents which can safely trigger the immune system to protect the body against SARS-CoV-2, creating a promising new vehicle for vaccine delivery. Hamilton, ON, Mar. 11, 2022— Physicists, […].

Engineer 81

Engineer Research Vaccination Vaccine 81

XTalks

MAY 7, 2021

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 That analysis also showed that the Novavax COVID-19 vaccine was 96.4

Protein 97

Protein Vaccination Vaccine Trials 97

Drug Discovery World

FEBRUARY 12, 2024

million grant to engineer microbial cell factories to produce membrane proteins which will support future drug screening and sustainable chemical production. The Engineering Biology Mission Award was given by UK Research and Innovation (UKRI). A team from Aston University and the University of Warwick has secured a £1.8 ($2.2)

Research 105

Research Drugs Engineer Protein 105

Drug Discovery World

JULY 27, 2023

The Phase I study was a first-in-human trial to investigate safety, immunogenicity, and survival in patients with advanced NSCLC (defined as metastatic or locally advanced disease) when administered the allogeneic dendritic cell (DC) vaccine VAC2.

Vaccination 52

Vaccination Vaccine Engineer Clinical Trials 52

XTalks

FEBRUARY 21, 2024

Reichman recently held the position of Head of Global Vaccines Engineering Core Technologies and Asset Management at the GSK Vaccines headquarters in Belgium. Before that, he was the Senior Director of the Global GSK Vaccines Supply Chain.

Life Science 105

Life Science Development Antibody Vaccination 105

Drug Discovery World

NOVEMBER 20, 2023

Engineering biology is reshaping the world, from enabling the rapid development of vaccines to providing alternatives to petroleum fuels. Central to engineering biology is the design – or redesign – and assembly of biological components to generate a desired function.

DNA 69

DNA Engineer Antibody Gene 69

Pharmaceutical Technology

JULY 6, 2022

The mRNA technology was used for the development of the Covid-19 vaccine. CureVac sought fair compensation for infringement of a portfolio of its intellectual property rights used to produce and sell BioNTech and Pfizer’s mRNA Covid-19 vaccine, Comirnaty. Topic sponsors are not involved in the creation of editorial content.

Vaccination 182

Vaccination Vaccine Gene Therapy Engineer 182

Pfizer

APRIL 26, 2023

But the underlying question is always the same: How will Pfizer and BioNTech ensure a seamless distribution of our vaccine? With the pandemic still raging, our vaccine will be in high demand and, upon authorization or approval, rapidly utilized to help beat back the virus. In the U.S.,

Vaccination 52

Vaccination Vaccine Manufacturing Containment 52

Scienmag

JANUARY 6, 2021

Funding for device that gives vaccine and monitors response Credit: IMPACT, Swansea University Researchers at Swansea University have received £230,000 to develop the world’s first smart vaccine device that will both deliver the COVID-19 vaccine and measure its efficacy through monitoring the body’s associated response.

Vaccination 94

Vaccination Vaccine Research Development 94

Drug Discovery World

MAY 23, 2024

A team of scientists in the US and the UK are combining a genetically modified cold sore virus with a cancer vaccine to treat an aggressive type of brain cancer in children. The researchers will use a genetically engineered herpes simplex virus type 1 to eliminate cancer cells. million of funding for this research project.

Genetic Engineering 59

Genetic Engineering Engineer Immune Response Vaccination 59

pharmaphorum

MARCH 30, 2022

CureVac and GlaxoSmithKline’s first attempt to develop a COVID-19 vaccine was a salutary reminder of the pitfalls in drug development, as the mRNA shot crashed and burned in a clinical trial last year, but they aren’t giving up. ” The post CureVac and GSK try again with COVID-19 vaccine appeared first on.

Vaccination 62

Vaccination Vaccine Protein Antibody 62

Scienmag

FEBRUARY 1, 2021

Credit: The Grainger College of Engineering As the numbers of those infected with COVID-19 has continued to climb, the desperate need for a vaccine was apparent. Even now with the invention and administration of several COVID-19 vaccinations, the question remains: How effective are these vaccines?

Antibody 98

Antibody Engineer Vaccination Vaccine 98

Scienmag

JANUARY 4, 2021

In advance of public vaccination, a quick and accurate COVID-19 antibody test will help determine the presence of neutralizing antibodies, the molecules that aid in protection against the virus. Credit: UAB BIRMINGHAM, Ala.

Vaccination 98

Vaccination Vaccine Antibody Development 98

Pharmaceutical Technology

MAY 31, 2023

Anocca’s platform features libraries of engineered human cells that allow for standardised analysis of T-cell biology, per the company’s website. In turn, the company also has proprietary tools that can identify and engineer T-cell receptors that can be further developed into potential cancer treatments.

Gene Therapy 130

Gene Therapy Gene Engineer Vaccination 130

Pharmaceutical Technology

FEBRUARY 3, 2023

Merck chairman and CEO Robert Davis said: “2022 was an exceptional year for Merck, which is a testament to the profound impact our medicines and vaccines are having on patients globally. “I I am extremely proud of what our talented and dedicated colleagues have accomplished scientifically, commercially and operationally.

Sales 246

Sales Engineer Vaccination Vaccine 246